Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 3
2011 1
2019 5
2020 4
2021 9
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Mutation-Driven Therapy in MDS.
Swoboda DM, Sallman DA. Swoboda DM, et al. Curr Hematol Malig Rep. 2019 Dec;14(6):550-560. doi: 10.1007/s11899-019-00554-4. Curr Hematol Malig Rep. 2019. PMID: 31760573 Review.
Novel therapies in myelodysplastic syndromes.
Swoboda DM, Gesiotto Q, Sallman DA. Swoboda DM, et al. Curr Opin Hematol. 2020 Mar;27(2):58-65. doi: 10.1097/MOH.0000000000000562. Curr Opin Hematol. 2020. PMID: 31972686 Review.
T315I-mutated myeloid sarcoma.
Zhang Y, Swoboda DM, Grover A, Nodzon L, Zhang L, Pinilla-Ibarz J. Zhang Y, et al. Among authors: swoboda dm. Leuk Res Rep. 2019 Aug 17;12:100184. doi: 10.1016/j.lrr.2019.100184. eCollection 2019. Leuk Res Rep. 2019. PMID: 31485411 Free PMC article.
PTPN11 mutations are associated with poor outcomes across myeloid malignancies.
Swoboda DM, Ali NA, Chan O, Padron E, Kuykendall AT, Song J, Hussaini M, Talati C, Sweet K, Lancet JE, Sallman DA, Komrokji RS. Swoboda DM, et al. Leukemia. 2021 Jan;35(1):286-288. doi: 10.1038/s41375-020-01083-3. Epub 2020 Nov 1. Leukemia. 2021. PMID: 33132383 No abstract available.
Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies.
Gesiotto QJ, Swoboda DM, Shallis RM, Al Ali N, Padron E, Kuykendall AT, Song J, Talati C, Sweet K, Lancet JE, Zeidan AM, Komrokji RS, Sallman DA. Gesiotto QJ, et al. Among authors: swoboda dm. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):421-424.e2. doi: 10.1016/j.clml.2021.01.010. Epub 2021 Jan 20. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33583730 No abstract available.
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts.
Swoboda DM, Kanagal-Shamanna R, Brunner AM, Cluzeau T, Chan O, Al Ali N, Montalban-Bravo G, Gesiotto QJ, Gavralidis A, Hunter AM, Lee JH, Kuykendall AT, Talati C, Sweet KL, Lancet JE, Padron E, Hussaini M, Song J, Garcia-Manero G, Komrokji RS, Sallman DA. Swoboda DM, et al. Leukemia. 2022 Jan 3. doi: 10.1038/s41375-021-01486-w. Online ahead of print. Leukemia. 2022. PMID: 34975158 No abstract available.
22 results